These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24372775)

  • 1. Cumulative risk of developing prostate cancer in men with low (≤ 2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan.
    Sawada K; Kitagawa Y; Ito K; Takeda Y; Mizokami A; Namiki M
    Int J Urol; 2014 Jun; 21(6):560-5. PubMed ID: 24372775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
    Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
    Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
    World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
    Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
    J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
    Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.
    Gelfond J; Choate K; Ankerst DP; Hernandez J; Leach RJ; Thompson IM
    J Urol; 2015 Jul; 194(1):46-51. PubMed ID: 25686543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
    Schröder FH; Roobol MJ; Andriole GL; Fleshner N
    J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
    J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and prostate-specific antigen kinetics of prostate cancer detected in repeat annual population screening in Japan.
    Kitagawa Y; Sawada K; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Takeda Y; Namiki M
    Int J Urol; 2014 May; 21(5):461-5. PubMed ID: 24134337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
    Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
    J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.